Síndrome Coronario Agudo

Hemos recopilado para ti todas las ponencias sobre síndrome coronario agudo (SCA) que se realizaron en Munich (Alemania) durante el ESC Congress 2008.

Síndrome Coronario Agudo (SCA)

Mesa científica	Título	Ponente
Fallacies from clinical trials	Percutaneous coronary intervention	Califf R M (Durham, US)
The new 'universal' definition of myocardial infarction	What has changed?	Thygesen (Aarhus C, DK)
The new 'universal' definition of myocardial infarction	Decision limits and pitfalls of biomarkers	Jaffe A (Rochester, US)
The new 'universal' definition of myocardial infarction	Implications for clinical practice	Hamm C W (Bad Nauheim, DE)
The new 'universal' definition of myocardial infarction	Implications for clinical trials	Simoons M L (Rotterdam, NL)
Clinical Trial Update I	Prasugrel Compared with Clopidogrel in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.- Discussant	Neumann F J (Bad Krozingen, DE)
Clinical Trial Update I	Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with STEMI: the HORIZONS AMI Trial	Mehran R (New York, US)
Clinical Trial Update I	Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with STEMI: the HORIZONS AMI Trial - Discussant	Califf R M (Durham, US)
Clinical Trial Update I	Polish-Italian-Hungarian Randomized Thrombectomy Trial (PIHRATE trial)	Dudek D (Krakow, PL)
Clinical Trial Update I	Polish-Italian-Hungarian Randomized Thrombectomy Trial (PIHRATE trial). - Discussant	De Feyter P J (Rotterdam, NL)
Clinical Trial Update I	One-year results of the Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI) trial. - Discussant	Weaver W D (Detroit, US)
Clinical Trial Update I	The effect of the pre-hospital initiation of a glycoprotein 2b/3a recepter blocker in patients undergoing primary angioplasty for acute myocardial infarction. Results of the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 Trial. - Discus	Ardissino D (Parma, IT)
Hot Line II	The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study	Mohr F W (Leipzig, DE)
Hot Line II	The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study	Serruys P W (Rotterdam, NL)
Hot Line II	The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study - Discussant - The cardiologist's point of view	Hamm C W (Bad Nauheim, DE)
Hot Line II	The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study - Discussant - The surgeon's point of view	Jones R H (Durham, US)
Hot Line II	LEADERS - Limus Eluted from A Durable versus Erodable stent coating (Randomized Comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent for percutaneous coronary intervention	Windecker S (Bern, CH)
Hot Line II	LEADERS - Limus Eluted from A Durable versus Erodable stent coating (Randomized Comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent for percutaneous coronary intervention - Discussant	Mauri L (Boston, US)
The new ESC guidelines	Acute Coronary Syndromes (ACS) with ST-elevation	Van de Werf F (Leuven, BE)
Safety of drug-eluting stents: two years after Barcelona	Lessons from registries	Harrington R A (Durham, US)
Safety of drug-eluting stents: two years after Barcelona	Latest data from randomised trials	Kastrati A (Munchen, DE)
Safety of drug-eluting stents: two years after Barcelona	Antiplatelet therapy	Jaffe R (Haifa, IL)
Hot Line III	The Effects of the Direct Lipoprotein -associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Athlerosclerotic Plaque	Wijns W (Aalst, BE)
Hot Line III	The Effects of the Direct Lipoprotein -associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Athlerosclerotic Plaque - Discussant	Crea F (Roma, IT)
Hot Line III	Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: Results of the APPRAISE-I dose guiding trial	Alexander J (Durham, US)
Hot Line III	Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: Results of the APPRAISE-I dose guiding trial - Discussant	Van de Werf F (Leuven, BE)
Hot Line III	Main Results of the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin or Resistance to clopidogrel study (3T/2R)	Valgimigli M (Ferrara, IT)
Hot Line III	Main Results of the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin or Resistance to clopidogrel study (3T/2R) - Discussant	Verheugt FWA (Nijmegen, NL)
Hot Line III	A Multicenter, Double blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 on Ischemia Reperfusion Injury in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (The F.I.R.E Trial)	Atar D (Oslo, NO)
Highlight Session	Acute Coronary Syndromes (ACS)	Fox K A (Edinburgh, GB)
Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic	Highlights of the new US ST-elevation myocardial infarction guidelines.	E M Antman (Boston, US)
Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic	Highlights of the new European ST-elevation myocardial infarction guidelines.	F Van de Werf (Leuven, BE)
Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic	Are there significant differences?	R G Wilcox (Nottingham, GB)
Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic	When do we need a new update and on what specifically?	E R Bates (Ann Arbor, US)
Antithrombotic and antiplatelet treatment in coronary artery disease: 2008	Non ST-elevation acute coronary syndrome	D Ardissino (Parma, IT)
Antithrombotic and antiplatelet treatment in coronary artery disease: 2008	ST-elevation myocardial infarction	A Budaj (Warsaw, PL)
Antithrombotic and antiplatelet treatment in coronary artery disease: 2008	Efficacy versus safety	J-P Bassand (Besancon, FR)
Hot Line III	Discussant	M S Marber (London, GB)

Cardiología hoy | Blog

Guías clínicas

Agenda SEC

CardioPODCAST

Cursos SEC

Másteres y Posgrados

Formación SEC 2025

CardioTV

Síndrome Coronario Agudo

Síndrome Coronario Agudo (SCA)

Actualidad

Revista Española de Cardiología

REC: Interventional Cardiology

REC: CardioClinics

Socios estratégicos